Art Therapy in Progressive Supranuclear Palsy
Art Therapy in Progressive Supranuclear Palsy: Studying the Effect on Quality of Care
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of progressive supranuclear palsy
- Have the cognitive ability to provide informed consent
Exclusion Criteria:
- Primary neurological diagnosis other than progressive supranuclear palsy
- Cognition too impaired to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Art Therapy
psp patients enrolled into study
|
Art therapy at Art Therapy Studio, a well-established recommended art therapy leader since 1967 with extensive experience in virtual therapy for patients with medical needs.
Cheryl Pete, MA ATR-BC, a board-certified art therapist and the Clinical Director will complete the art therapy sessions.
The art therapy will be a 1-hour sessions, once a week for a total of 8 weeks (or 8 sessions).
Cheryl Pete's role will solely involve providing a service.
Chery will complete the Art Therapy according to her standard practices.
Cheryl's Art Therapy will not be altered in any way as a part of this research study.
Cheryl will not collect any research data.
As research participants are referred to Cheryl for the Art Therapy, the research participant's name and contact information will be shared.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PSP-QoL (Progressive Supranuclear Palsy Qualify of Life Scale)
Time Frame: 8-10 weeks
|
Self-reported quality of life rating scale comprising of 28 items in six categories: daily activities (by history), behavior, bulbar, ocular motor, limb motor and gait/midline.
Scores range from 0 to 100, each item graded 0-2 (six items) or 0-4 (22 items).
The lower the total score the better the quality of life.
|
8-10 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PHQ-9 (Patient Health Questionnaire-9)
Time Frame: 8-10 weeks
|
Self-reported depression rating scale comprising of 9 items.
The lower the total score means that depression is absent or minimal.
|
8-10 weeks
|
|
NPI (Neuropsychiatric Inventory)
Time Frame: 8-10 weeks
|
Scale that is completed by the caregiver.
The scale is comprised of 12 items and will evaluate behavioral areas commonly affected in patients with dementia.
The lower the total score means that behavior is intact
|
8-10 weeks
|
|
Zarit Caregiver Burden Scale
Time Frame: 8-10 weeks
|
Scale that is completed by the caregiver.
The scale is comprised of 22 items and will evaluate the caregiver's level of burden.
The lower the total score means that the burden is absent.
|
8-10 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Chi-Ying Roy Lin, MD, MPH, Baylor College of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Eye Diseases
- Tauopathies
- Neurodegenerative Diseases
- Movement Disorders
- Basal Ganglia Diseases
- Cranial Nerve Diseases
- Ophthalmoplegia
- Ocular Motility Disorders
- Paralysis
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Supranuclear Palsy, Progressive
Other Study ID Numbers
Other Study ID Numbers
- H-54410
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.